Accueil>>Proteins>> Enzymes>> Phosphatase>>Fenvalerate-d5

Fenvalerate-d5

Catalog No.GC63327

Products are for research use only. Not for human use. We do not sell to patients.

Fenvalerate-d5 Chemical Structure

Cas No.: 1246815-00-8

Taille Prix Stock Qté
1 mg
108,00 $US
En stock
5 mg
252,00 $US
En stock
10 mg
432,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Fenvalerate-d5 is the deuterium labeled Fenvalerate. Fenvalerate is a potent protein phosphatase 2B (calcineurin) inhibitor with an IC50 of 2-4 nM for PP2B-Aα. Fenvalerate is a pyrethroid ester insecticide and acaricide[1].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. E Enan, et al. Specific Inhibition of Calcineurin by Type II Synthetic Pyrethroid Insecticides. Biochem Pharmacol. 1992 Apr 15;43(8):1777-84.;A R Reilein, et al. Regulation of Organelle Movement in Melanophores by Protein Kinase A (PKA), Protein Kinase C (PKC), and Protein Phosphatase 2A (PP2A). J Cell Biol. 1998 Aug 10;142(3):803-13.

Avis

Review for Fenvalerate-d5

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fenvalerate-d5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.